CJC-1295 vs Ipamorelin: Synergistic Growth Hormone Research (2026)

CJC-1295 vs Ipamorelin: The Popular GHRH and GHRP Combination

CJC-1295 and Ipamorelin are often discussed together because they are one of the most commonly stacked growth hormone research peptide combinations. Understanding each compound individually helps researchers design more effective protocols.

What Is CJC-1295?

CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH). It comes in two forms: with DAC (Drug Affinity Complex), which extends its half-life to approximately 6-8 days, and without DAC, which has a much shorter half-life of about 30 minutes. CJC-1295 with DAC is popular for sustained GH release protocols.

What Is Ipamorelin?

Ipamorelin is a growth hormone secretagogue (GHRP) pentapeptide that stimulates GH release with high selectivity. Its short half-life (~2 hours) makes it suitable for multiple daily administrations. It is valued for minimal effects on prolactin and cortisol.

Why They Are Stacked

The CJC-1295 + Ipamorelin stack pairs a GHRH analog with a GHRP secretagogue. The GHRH component provides a sustained baseline of GH release signaling, while the GHRP component amplifies GH pulses. This synergistic approach is among the most popular in growth hormone research.

For detailed protocols, see our peptide stacking guide and GHRP/GHRH analog guide.

Dosing Considerations

Typical research protocols: CJC-1295 with DAC at 1-2 mg twice weekly, or CJC-1295 without DAC at 100-200 mcg daily with Ipamorelin at 200-500 mcg daily. Both are administered subcutaneously after reconstitution. Follow our reconstitution guide for best practices.

Where to Buy

Both CJC-1295 No DAC and Ipamorelin are available at Hanpro Peptides. Explore the full catalog for all research peptides.

Conclusion

CJC-1295 and Ipamorelin work through complementary mechanisms, making their combination a powerful tool for growth hormone research. Choosing the right DAC version of CJC-1295 depends on your protocol frequency preferences.